Arcus Biosciences
RCUSArcus Biosciences is a late clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small molecules and antibodies for cancer, inflammatory, and autoimmune diseases.
Earnings
Next report
Oct 27, 2026 (in a month)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Arcus Biosciences is a late clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small molecules and antibodies for cancer, inflammatory, and autoimmune diseases. The company leverages an internal small-molecule discovery engine to create a pipeline of potential best-in-class therapies, often designed to improve upon validated biological targets. Its primary value proposition lies in its ability to advance multiple high-potential programs through strategic global collaborations and internal development capabilities.
Arcus maintains a strong competitive position through a significant strategic partnership with Gilead Sciences and a pipeline of molecules designed for superior pharmacokinetic profiles compared to existing approved therapies.
FAQ
- What is Arcus Biosciences's market cap?
- Arcus Biosciences (RCUS) has a market capitalization of $3.1B and trades on NYSE.
- What is Arcus Biosciences's revenue and profitability?
- Arcus Biosciences generated $117.0M in trailing twelve-month revenue with a net loss of $460.0M, representing a net margin of -393.2%, with free cash flow of -$475.0M. The latest reported period is Q2 2026.
- Who are Arcus Biosciences's competitors?
- Arcus Biosciences's key competitors include Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and others. These companies compete in similar markets and product categories.
- Who does Arcus Biosciences partner with?
- Arcus Biosciences's notable partners include Gilead Sciences, Inc., Taiho Pharmaceutical Co., Ltd., WuXi Biologics Ireland Limited, and others.
- Where is Arcus Biosciences headquartered?
- Arcus Biosciences is headquartered in United States of America and employs approximately 577 people. It has been publicly traded since 2018.
